Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
RemeGen Co. Ltd. Class A (688331.SS)
Yantai, HN, CN
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.50% | -0.25% | -10.27% | +17.59% | +16.38% | +49.16% | +96.69% | +81.72% | +184.11% | +184.11% | +184.11% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+89.4% ★ Q1'26: +24.8% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+147.3% ★ Q1'26: +228.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+9.1% Q1'26: -4.7% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+21.8% ★ Q1'26: -3.9% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+20.9% ★ Q1'26: -3.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+2.1% Q1'26: +1.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×2.34× ★ Q1'26: -20.23× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 14 Rev. Ana. 4 EPS Ana. |
Dec 2027 16 Rev. Ana. 2 EPS Ana. |
Dec 2028 14 Rev. Ana. 3 EPS Ana. |
Dec 2029 15 Rev. Ana. 4 EPS Ana. |
Dec 2030 15 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 3.59M (-100.0%)
|
1.42B
est: 1.36B (+4.4%)
|
772.11M
est: 807.60M (-4.4%)
|
1.08B
est: 1.12B (-3.3%)
|
1.72B
est: 1.70B (+0.9%)
|
3.25B
est: 3.01B (+8.1%)
|
7.26B
5.64B – 8.40B
+141.3% YoY
|
4.85B
3.84B – 6.08B
-33.2% YoY
|
6.06B
4.75B – 7.26B
+25.2% YoY
|
9.83B
7.71B – 11.77B
+62.1% YoY
|
10.67B
8.37B – 12.78B
+8.5% YoY
|
| EBITDA |
-618.70M
est: -1.12M (-54,991.2%)
|
347.82M
est: -426.41M (+181.6%)
|
-868.04M
est: -252.51M (-243.8%)
|
-1.31B
est: -350.16M (-274.7%)
|
-1.16B
est: -729.85M (-59.6%)
|
940.28M
est: -1.29B (+172.9%)
|
-3.11B
-3.61B – -2.42B
-141.3% YoY
|
-2.08B
-2.61B – -1.65B
+33.2% YoY
|
-2.60B
-3.11B – -2.04B
-25.2% YoY
|
-4.22B
-5.05B – -3.31B
-62.1% YoY
|
-4.58B
-5.48B – -3.59B
-8.5% YoY
|
| EBIT |
-668.60M
est: -1.25M (-53,254.4%)
|
281.58M
est: -475.80M (+159.2%)
|
-992.07M
est: -281.76M (-252.1%)
|
-1.49B
est: -390.72M (-280.9%)
|
-1.40B
est: -815.63M (-71.2%)
|
709.27M
est: -1.44B (+149.2%)
|
-3.48B
-4.03B – -2.71B
-141.3% YoY
|
-2.32B
-2.91B – -1.84B
+33.2% YoY
|
-2.91B
-3.48B – -2.28B
-25.2% YoY
|
-4.71B
-5.64B – -3.70B
-62.1% YoY
|
-5.12B
-6.12B – -4.01B
-8.5% YoY
|
| Net Income |
-697.82M
est: -635.15M (-9.9%)
|
276.26M
est: 207.22M (+33.3%)
|
-998.83M
est: -970.64M (-2.9%)
|
-1.51B
est: -1.32B (-14.7%)
|
-1.47B
est: -1.39B (-5.6%)
|
708.52M
est: 18.99M (+3,632.0%)
|
3.43B
2.46B – 4.30B
+17,949.0% YoY
|
932.30M
670.45M – 1.17B
-72.8% YoY
|
1.61B
1.16B – 2.03B
+73.2% YoY
|
3.99B
2.87B – 5.01B
+147.0% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
241.80M
est: -355.48M (+168.0%)
|
482.81M
est: -134.98B (+100.4%)
|
707.01M
est: -79.93B (+100.9%)
|
1.08B
est: -110.84B (+101.0%)
|
1.27B
est: 1.02B (+24.4%)
|
—
est: 1.80B (-100.0%)
|
4.34B
3.37B – 5.02B
+141.3% YoY
|
2.90B
2.30B – 3.63B
-33.2% YoY
|
3.63B
2.84B – 4.34B
+25.2% YoY
|
5.88B
4.61B – 7.04B
+62.1% YoY
|
6.38B
5.00B – 7.64B
+8.5% YoY
|
| EPS |
-1.71
est: -1.18 (-44.7%)
|
0.57
est: 0.39 (+47.9%)
|
-1.88
est: -1.81 (-4.1%)
|
-2.80
est: -2.45 (-14.2%)
|
-2.73
est: -2.53 (-7.8%)
|
1.29
est: 0.03 (+3,632.0%)
|
6.24
4.49 – 7.84
+17,949.0% YoY
|
1.70
1.22 – 2.13
-72.8% YoY
|
2.94
2.11 – 3.69
+73.2% YoY
|
7.26
5.22 – 9.12
+147.0% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 1.93% | 1.54M | 0.68% |
| 2 | KraneShares MSCI All China Health Care Index ETF KURE | 1.19% | 948.3K | 0.79% |
| 3 | Rayliant-ChinaAMC Transformative China Tech ETF CNQQ | 0.31% | 69.8K | 0.75% |
| 4 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.23% | 83.0K | 0.65% |
| 5 | iShares MSCI China A UCITS ETF CNYE.MI | 0.10% | 101.0K | 0.45% |
| 6 | iShares MSCI China A UCITS ETF CNYA.L | 0.10% | 3.06M | 0.40% |
| 7 | iShares MSCI China A ETF CNYA | 0.10% | 224.5K | 0.60% |
| 8 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.09% | 122.2K | 0.35% |
| 9 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.09% | 119.8K | 0.35% |
| 10 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.07% | 12.0K | 0.65% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jianmin Fang | Co-Founder, Chief Executive Officer, GM, Member of Scientific Advisory Board & Executive Director | 8M | — |
| Weidong Wang | Co-Founder & Executive Chairman | 3M | male |
| Jian Lin | Executive Director | 848.0K | male |
| Ming Shi | Chief Medical Officer | — | — |
| Qingkai Wen | Executive Director & Board Secretary | — | male |
| Shaojing Tong | Chief Financial Officer & Joint Company Secretary | — | male |
| Xiaoming Yang | Chief Manufacturing Officer | — | — |
| Zhulun Wang | Chief Scientific Officer | — | — |
| Kaisheng Huang | Chief Operating Officer | — | male |
| Marie Zhu | Chief Technical Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688331.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
